Found 188 clinical trials
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …
- 0 views
- 19 Feb, 2024
- 2 locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
- 0 views
- 19 Feb, 2024
- 22 locations
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
- 0 views
- 19 Feb, 2024
- 4 locations
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:
5-fraction SABR is a feasible, well-tolerated, effective and cost effective treatment for high-intermediate and high risk prostate cancer with/without an image-guided intraprostatic boost.
- 0 views
- 19 Feb, 2024
- 1 location
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer
Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic.
- 0 views
- 19 Feb, 2024
- 2 locations
HDR Brachytherapy 68-Ga-RM2 PET 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)
- 0 views
- 19 Feb, 2024
- 1 location
Interactive Decision Aid for Men Diagnosed With Prostate Cancer
Prostate cancer is the second leading cause of cancer related deaths in the western world (National Cancer Institute, 2011). Prostate cancer diagnosis relates to significant psychological distress (Roesch et al, 2005; Hervouet et al, 2005).
- 0 views
- 19 Feb, 2024
- 1 location
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …
- 0 views
- 19 Feb, 2024
- 1 location
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand
Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new positron emission tomography (PET) radiotracer …
- 0 views
- 19 Feb, 2024
- 1 location
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)
This increasingly allows individualized specific therapy of patients with prostate cancer recurrence. PSMA PET has now been included in national and international guidelines for the diagnosis of patients with biochemical recurrence of prostate cancer.
- 0 views
- 19 Feb, 2024
- 1 location